title: Overexpression of CCL20 and its receptor CCR6 predicts poor clinical prognosis in human gliomas.
abstract: Recent studies have demonstrated that the chemokine CCL20 and its receptor CCR6 may be involved in tumorigenesis, tumor progression and metastatic spread of various human malignancies. The aim of this study was to investigate the clinicopathological significance and prognostic value of CCL20 and CCR6 expression in human malignant glioma. CCL20 and CCR6 expression in human gliomas and nonneoplastic brain tissues was measured by immunohistochemistry. The association of CCL20 and CCR6 expression with clinicopathological factors or prognosis in glioma patients was statistically analyzed. The expression levels of CCL20 and CCR6 proteins were both up-regulated in glioma tissues. There was a significantly positive correlation between the expression of the two markers (r = 0.88; P < 0.001). In addition, the overexpressions of CCL20 and CCR6 were both detected in high-grade glioma tissues compared with those in low-grade tissues and increased with ascending tumor World Health Organization (WHO) grades (P = 0.006 and 0.008, respectively). The increased expressions of CCL20 and CCR6 proteins were also significantly correlated with low Karnofsky performance score (both P = 0.01). Moreover, univariate analysis found that CCL20 expression (P = 0.002), CCR6 expression (P = 0.002) and CCL20/CCR6 co-expression (P < 0.001) were all significantly associated with poor prognosis. In particular, glioma patients with CCL20/CCR6 co-expression have the shortest overall survival. Multivariate analysis further identified the expression levels of CCL20 and CCR6 to be independent prognostic factors. Our data suggest for the first time that CCL20 and CCR6 might play an important role in the regulation of aggressiveness in human gliomas. The up-regulation of CCL20 and CCR6 might be closely associated with poor clinical outcome of patients with gliomas.
authors.affiliation: Department of Neurosurgery, Tangdu Hospital, No. 569, Xinsi Road, Baqiao District, Xi'an City, 710038, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.forename: Huaizhou
authors.initials: H
authors.lastname: Qin
authors.forename: Lihong
authors.initials: L
authors.lastname: Li
authors.forename: Yongsheng
authors.initials: Y
authors.lastname: Zhang
authors.forename: Yanyang
authors.initials: Y
authors.lastname: Tu
authors.forename: Fuqiang
authors.initials: F
authors.lastname: Feng
authors.forename: Peigang
authors.initials: P
authors.lastname: Ji
authors.forename: Jingyu
authors.initials: J
authors.lastname: Zhang
authors.forename: Gang
authors.initials: G
authors.lastname: Li
authors.forename: Zhenwei
authors.initials: Z
authors.lastname: Zhao
authors.forename: Guodong
authors.initials: G
authors.lastname: Gao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D054418:Chemokine CCL20 / Q000032:analysis / Q000096:biosynthesis*; D002648:Child; D005260:Female; D005910:Glioma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D054399:Receptors, CCR6 / Q000032:analysis / Q000096:biosynthesis*; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C108355:CCL20 protein, human; C106311:CCR6 protein, human; D054418:Chemokine CCL20; D054399:Receptors, CCR6